SciSparc Ltd. Regains Compliance With Nasdaq Minimum Bid Price Notification
SciSparc Ltd. Regains Compliance With Nasdaq Minimum Bid Price Notification
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Amazon.com Marketplace.Tel Aviv, Oct. 16, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company"), reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.
特拉维夫，2023年10月16日(环球网)--纳斯达克：SPRC是一家专注于开发治疗中枢神经系统疾病疗法的专业临床阶段制药公司(以下简称“公司”)，该公司报告收到纳斯达克股票市场有限责任公司(“纳斯达克”)的正式通知，称公司已重新遵守上市规则第5550(A)(2)条，该规则要求公司普通股维持每股1.00美元的最低出价。
The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.
纳斯达克工作人员是在公司普通股连续10个工作日的收盘价为每股1.00美元或更高后做出这一合规判断的。因此，本公司已恢复遵守纳斯达克上市规则第5550(A)(2)条，而纳斯达克认为先前的投标价格不足事宜现已结束。
About SciSparc Ltd. (Nasdaq:SPRC):
关于本公司(纳斯达克市场代码：SPRC)：
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Amazon.com Marketplace.
SciSparc有限公司是一家专业的临床阶段制药公司，由一支经验丰富的高级管理人员和科学家团队领导。本组织的重点是创建和加强以大麻类药物为基础的技术和资产组合。在这一重点上，该公司目前从事以下基于THC和/或非精神活性大麻二醇(CBD)的药物开发计划：用于治疗抽动症的SCI-110，用于治疗阿尔茨海默病和激动症的SCI-110；用于治疗疼痛的SCI-160；以及用于治疗自闭症谱系障碍和癫痫持续状态的SCI-210。该公司还拥有一家子公司的控股权，该子公司的业务重点是在亚马逊市场上销售大麻种子的油基产品。
For further information please refer to information available on the Company's website:
欲了解更多信息，请参阅公司网站上的信息：
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
投资者联系方式：
邮箱：ir@scisparc.com
电话：+9723-6167055